Correlation of Neutrophil-Lymphocyte Ratio, Alpha-Fetoprotein, and PIVKA-II with Staging of HCC Related HBV at Dr. Mohammad Hoesin Hospital, Palembang
), Suyata Suyata(2), Legiran .(3),
(1) Division of Gastroentero-Hepatology, Department of Internal Medicine, Faculty of Medicine Sriwijaya University/Dr. Mohammad Hoesin General Hospital, Palembang
(2) Department of Internal Medicine, Faculty of Medicine Sriwijaya University/Dr. Mohammad Hoesin General Hospital, Palembang
(3) Department of Anatomy, Faculty of Medicine, Sriwijaya University, South of Sumatra
Corresponding Author
Abstract
Background: The staging of Hepatocellular carcinoma (HCC) requires evaluating the tumor size and number, liver function, physical performance, tumor invasion, extrahepatic metastasis, and clinical symptoms. Biomarkers such as neutrophil-lymphocyte ratio (NLR), alpha-fetoprotein (AFP), and protein induced by the absence of vitamin K or antagonist-II (PIVKA-II) have been identified as valuable diagnostic and prognostic tools for HCC. This study aims to investigate the correlation between NLR, AFP, and PIVKA-II and HCC stages.
Methods: This observational study was conducted at the Department of Internal Medicine, Dr. Mohammad Hoesin Hospital, Palembang, from April to July 2024. HCC stages were classified using the Barcelona Clinic Liver Cancer (BCLC) system. NLR, AFP, and PIVKA-II levels were measured using ELISA method. Data were analyzed susing one-way ANOVA or the Kruskal-Wallis test.
Results: A total of 38 patients with HCC who met the inclusion criteria were included in the study. There was a weak positive correlation between NLR and HCC stage (r = 0.334; p = 0.040), a moderate positive correlation between AFP and HCC stage (r = 0.499; p = 0.001), and a strong positive correlation between PIVKA-II and HCC stage (r = 0.797; p = 0.000). PIVKA-II and AFP were found to have a significant sequential effect on the BCLC stage.
Conclusion: PIVKA-II and AFP are significant indicators for assessing BCLC stages, offering valuable support for the diagnosis and management of HCC.
Keywords
References
Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez-Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol [Internet]. 2006;5(1):16–24. Available from: http://dx.doi.org/10.1016/S1665-2681(19)32034-4
Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology [Internet]. 2017;152(4):745–61. Available from: http://dx.doi.org/10.1053/j.gastro.2016.11.048
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
An S, Zhan X, Liu M, Li L, Wu J. Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers. Diagnostics. 2023;13(8).
Kobeissy A, Merza N, Al-Hillan A, Boujemaa S, Ahmed Z, Nawras M, et al. Protein Induced by Vitamin K Absence or Antagonist-II Versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis. J Clin Med Res [Internet]. 2023;15(7):343–59. Available from: https://www.doi.org/10.14740/jocmr4951
He C, Mao Y, Lao X, Li S, Lin X. Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma. Oncol Lett. 2018;15(4):4262–8.
Xu C, Wu F, Du L, Dong Y, Lin S. Significant association between high neutrophil-lymphocyte ratio and poor prognosis in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol. 2023;14(September):1–12.
Suehiro T, Sugimachi K, Matsumata T, Itasaka H, Taketomi A, Maeda T. Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma. Comparison with alpha‐fetoprotein. Cancer. 1994;73(10):2464–71.
Hu W tan, Ji X ying, Jiang Z liang, Liu Y, Luo H yin, Zhang DX, et al. Gene & Protein in Disease Application of multiple inflammatory markers combined with PIVKA-II in differential diagnosis of AFP-NHCC. Gene Protein Dis. 2024;3(4):1–10.
Haydon GH, Hayes PC. Hepatocellular carcinoma. Vol. 53, British Journal of Hospital Medicine. 1995. 74–80 p.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim [Internet]. 2021;7(1). Available from: http://dx.doi.org/10.1038/s41572-020-00240-3
Ding Z, Wang L, Sun J, Zheng L, Tang Y, Tang H. Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances. Front Oncol. 2025;15(April):1–16.
Dai T, Lin G, Deng M, Zhu S, Li H, Yao J, et al. The prognostic significance of neutrophil-to-lymphocyte ratio at different time points in patients with hepatocellular carcinoma receiving liver resection. Transl Cancer Res. 2020;9(2):441–57.
Lin S, Hu S, Ran Y, Wu F. Neutrophil-to-lymphocyte ratio predicts prognosis of patients with hepatocellular carcinoma: A systematic review and meta-analysis. Transl Cancer Res. 2021;10(4):1667–78.
Li W, Liu K, Chen Y, Zhu M, Li M. Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance. Curr Med Chem. 2020;28(6):1126–42.
Ramadhini AS. Korelasi Serum Alfa-Fetoprotein (AFP) dengan Tingkat Keparahan Karsinoma Hepatoseluler Berdasarkan Sistem Staging Barcelona Clinic Liver Cancer (BCLC) di RSUP Dr. Sardjito Yogyakarta [Internet]. Universitas Gajah Mada; 2022. Available from: http://etd.repository.ugm.ac.id/
Yao WJ, Chang TT, Wang ST, Chow NH, Lin PW, Chang YC, et al. Clinicopathologic correlation of serum tissue polypeptide specific antigen in hepatocellular carcinoma. Oncology. 2001;61(1):64–70.
Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep [Internet]. 2017;7(1):1–9. Available from: http://dx.doi.org/10.1038/s41598-017-12834-1
Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer. 2021;21(1):1–10.
Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol. 2021;11(November):1–10.
Wang SY, Su TH, Chen B bin, Liu CJ, Liu CH, Yang HC, et al. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma. J Formos Med Assoc [Internet]. 2022;121(8):1579–87. Available from: https://doi.org/10.1016/j.jfma.2022.01.005
Hadi H, Wan Shuaib WMA, Raja Ali RA, Othman H. Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients. Med. 2022;58(8):1–11.
Nugraha BE, Setiawan N, Susianti H, Pratomo B. Differences Between Alpha-Fetoprotein (AFP) and Prothrombin Induced by Vitamin K Absence or antagonist II (PIVKA-II) Values as Early Detection Method for Hepatocellular Carcinoma (HCC) and Cirrhosis. Indones J Gastroenterol Hepatol Dig Endosc. 2020;19(3):153–7.
Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, et al. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis b virus-associated hepatocellular carcinoma. World J Gastroenterol. 2015;21(13):3928–35.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
Nevola R, Tortorella G, Rosato V, Rinaldi L, Imbriani S, Perillo P, et al. Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma. Biology (Basel). 2023;12(7):1–25.
Chen J, Wang X, Ye W. Prognostic analysis of sex and age in hepatocellular carcinoma: A SEER study. Eur J Gastroenterol Hepatol. 2024;36(5):646–51.
Liou WL, Tan TJY, Chen K, Goh GBB, Chang JPE, Tan CK. Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades. JGH Open. 2023;7(5):377–86.
Wu EM, Wong LL, Hernandez BY, Ji J fang, Jia W, Sandi A, et al. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 2018;4:1–17.
Iyer JK, Kalra M, Kaul A, Payton ME, Kaul R. Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol. 2017;23(37):6802–16.
Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147(2):317–30.
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of the hepatocellular carcinoma. Hepatology2. 21AD;73(Suppl 1):4–13.
Ali AAK, Gamal S El, Anwar R, Elzahaf E, Eskandere D. Assessment of clinico-epidemiological profile of Hepatocellular carcinoma in the last two decades. Egypt J Intern Med [Internet]. 2023;35(1). Available from: https://doi.org/10.1186/s43162-023-00201-8
Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, et al. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY). 2021;13(19):23416–34.
El-Domiaty N, Saliba F, Karam V, Sobesky R, Ibrahim W, Vibert E, et al. Impact of body mass index on hepatocellular carcinoma recurrence after liver transplantation through long-term follow-up. Hepatobiliary Surg Nutr. 2021;10(5):598–609.
Cha B, Yu JH, Jin YJ, Suh YJ, Lee JW. Survival Outcomes According to Body Mass Index in Hepatocellular Carcinoma Patient: Analysis of Nationwide Cancer Registry Database. Sci Rep. 2020;10(1):1–9.
Park NH, Song IH, Chung YH. Molecular pathogenesis of hepatitis C virus-associated hepatocellular carcinoma. Gut Liver. 2007;1(2):101–17.
Zhang M, Chen H, Liu H, Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark Res. 2024;12(1):1–16.
Aly A, Fulcher N, Seal B, Pham T, Wang Y, Paulson S, et al. Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting. Hepatic Oncol. 2023;10(1).
Bartolini I, Nelli T, Russolillo N, Cucchetti A, Pesi B, Moraldi L, et al. Multiple hepatocellular carcinoma: Long-term outcomes following resection beyond actual guidelines. An Italian multicentric retrospective study. Am J Surg [Internet]. 2021;222(3):599–605. Available from: https://doi.org/10.1016/j.amjsurg.2021.01.023
Sung PS, Jang JW. Natural killer cell dysfunction in hepatocellular carcinoma: Pathogenesis and clinical implications. Int J Mol Sci. 2018;19(11).
Zhong X, Lv M, Ma MQ, Huang Q, Hu R, Li J, et al. State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy. Biomed Pharmacother [Internet]. 2023;165(May):115131. Available from: https://doi.org/10.1016/j.biopha.2023.115131
Roy AM, Iyer R, Chakraborty S. The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability. Cell Reports Med [Internet]. 2023;4(9):101170. Available from: https://doi.org/10.1016/j.xcrm.2023.101170
Tanwar S, Rhodes F, Srivastava A, Trembling PM, Rosenberg WM. Inflammation and fibrosis in chronic liver diseases including nonalcoholic fatty liver disease and hepatitis C. World J Gastroenterol. 2020;26(8):109–33.
Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation. J Hepatol [Internet]. 2024;81(5):895–910. Available from: https://doi.org/10.1016/j.jhep.2024.06.016
Obeagu EI. Neutrophil-driven tumor inflammation in breast cancer Pathways and therapeutic implications: A narrative review. Med (United States). 2025;104(25):e43024.
Brempelis KJ, Crispe IN. Infiltrating monocytes in liver injury and repair. Clin Transl Immunol. 2016;5(11).
Stauffer JK, Scarzello AJ, Jiang Q, Qiltrout RH. Chronic Inflammation, Immune Escape and Oncogenesis In the Liver : A Unique Neighborhood for Novel Intersections. Hepatology [Internet]. 2013;1–13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf
Li S, Hong M, Tan HY, Wang N, Feng Y. Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases. Oxid Med Cell Longev. 2016;2016.
Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res. 2011;185:135–48.
Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. Sci Rep [Internet]. 2021;11(1):1–9. Available from: https://doi.org/10.1038/s41598-020-79431-7
Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol [Internet]. 2021;74(2):350–9. Available from: http://dx.doi.org/10.1016/j.jhep.2020.08.010
Wang C, Wang M, Zhang X, Zhao S, Hu J, Han G, et al. The neutrophil-to-lymphocyte ratio is a predictive factor for the survival of patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Transl Med. 2020;8(8):541–541.
Murray MJ, Nicholson JC. α-Fetoprotein. Arch Dis Child Educ Pract Ed. 2011;96(4):141–7.
Wang X, Wang Q. Alpha-fetoprotein and hepatocellular carcinoma immunity. Can J Gastroenterol Hepatol. 2018;2018.
Sauzay C, Petit A, Bourgeois AM, Barbare JC, Chauffert B, Galmiche A, et al. Alpha-foetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. Clin Chim Acta [Internet]. 2016;463:39–44. Available from: http://dx.doi.org/10.1016/j.cca.2016.10.006
Xu Y, Guo Q, Wei L. The emerging influences of alpha-fetoprotein in the tumorigenesis and progression of hepatocellular carcinoma. Cancers (Basel). 2021;13(20).
Park H, Park JY. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma. Biomed Res Int. 2013;2013.
Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17(1):1–10.
Xing H, Yan C, Cheng L, Wang N, Dai S, Yuan J, et al. Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. Tumor Biol [Internet]. 2016;37(12):15447–56. Available from: http://dx.doi.org/10.1007/s13277-016-5443-x
Article Metrics
Abstract View
: 182 times
Download : 99 times
DOI: 10.24871/2632025219-227
Refbacks
- There are currently no refbacks.
